Press "Enter" to skip to content

The data were shown at the 2011 Consortium of Multiple Sclerosis Centers Annual Meeting.

AMPYRA ER Tablets improve taking walks ability in patients with multiple sclerosis Acorda Therapeutics, Inc . The data were shown at the 2011 Consortium of Multiple Sclerosis Centers Annual Meeting, june 1-4 in Montreal held, Canada. AMPYRA can be an oral medication accepted by the U.S. Food and Medication Administration as cure to boost walking in individuals with multiple sclerosis . This was demonstrated by a rise in walking speed. People who have MS often knowledge a progressive decline within their walking ability that can begin early in their disease course. However, in many cases patients and their health care providers usually do not discuss strolling impairment until it is so severe that it needs physical support from canes or walkers, said Ron Cohen, M.D., Acorda’s President and CEO.

During the second quarter, AMAG initiated enrollment in its global registrational program for Feraheme for the treating iron deficiency anemia, whatever the underlying cause. The estimated 1,400-patient program includes two phase III studies, one comparing treatment with Feraheme to placebo, and the various other evaluating treatment with Feraheme to treatment with intravenous iron sucrose. The ongoing company plans to complete enrollment in the program by year end 2011. Feraheme Start Highlights AMAG reported second one fourth 2010 Feraheme net product revenues of $16.0 million, including $2.4 million of revenues previously deferred under its Feraheme release incentive program.